Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Benralizumab in Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03563066
Recruitment Status : Recruiting
First Posted : June 20, 2018
Last Update Posted : March 8, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
McMaster University

Brief Summary:
Atopic Dermatitis (AD), also known as eczema, is a common skin disease characterized by itchy lesions. The prevalence of AD has increased over the past few decades, with 15-30% of children and 2-10%of adults being affected. The lesions of AD patients are very inflamed, with an increased number of inflammatory cells in the skin. There are not many medications available that are fully effective and can be used long-term for treatment of atopic dermatitis. Benralizumab is a monoclonal antibody used for treatment of a type of asthma called "eosinophilic asthma". Atopic dermatitis is also associated with elevated levels of eosinophils, and we would like to determine if benralizumab is effective in patients with atopic dermatitis. This is a randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect of 3 doses of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) every 4 weeks to patients with moderate-to-severe atopic dermatitis, on the severity of atopic dermatitis, and the cellular inflammation of skin lesions in these patients. Anti-inflammatory properties of benralizumab when a skin flare is induced in a controlled laboratory setting, in addition to the effects of benralizumab on skin that is already inflamed will be examined.It is hypothesized that benralizumab will attenuate eosinophilic inflammation in the skin.

Condition or disease Intervention/treatment Phase
Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Drug: Benralizumab Drug: Placebo Control Phase 2

Detailed Description:

Patients with a history of moderate-to-severe atopic dermatitis will enter a screening period (Days -3 to -1) to assess responses to intradermal allergen challenge. Those developing a late cutaneous response 24 hours post-intradermal allergen challenge will be recruited for the study and have the size of the wheal/flare measured. A punch biopsy obtained from the challenge site and samples of peripheral blood and skin lesions will be obtained. Prior to randomization, skin lesions will be graded using the validated Eczema Area and Severity Index (EASI) Score as a baseline measure of the severity of disease. Patients will then be randomized 1:1 to benralizumab (30 mg SC monthly) or placebo, with dosing at days 0, 28 and 56 (± 3 days). On Day 64 (1 week after the last dose of study drug), an intradermal allergen challenge will be conducted to determine the effect of benralizumab on allergen-induced responses in skin. On Day 65 (24 hours post-intradermal allergen challenge), the size of the wheal/flare will be measured and a punch biopsy will be obtained from the challenge site and samples peripheral blood and skin lesions will be obtained. Skin lesions will be reassessed clinically on Day 65 using the EASI score to assess the effect of benralizumab on changes to the severity of disease. A safety followup visit will take place at week 20, which is 140 days after the first dose (12 weeks after the last dose/11 weeks after the last study procedure).

Primary endpoint

1. The number of eosinophils per millimetre squared of skin, measured 24 hours post intradermal allergen challenge, 65 days after the first dose. The number of eosinophils in the skin will be assessed by histological examination of a punch skin biopsy obtained from the site of the intradermal allergen challenge.

Secondary endpoints

  1. The number of basophils per millimetre squared of skin, measured 24 hours post intradermal allergen challenge, after 65 days of dosing. The number of basophils in the skin will be assessed by immunohistochemistry of a punch skin biopsy obtained from the site of the intradermal allergen challenge, using a commercial antibody specific for basophils.
  2. The size of the late cutaneous response, measured 24 hours post intradermal allergen challenge, 65 days after the first dose. The late cutaneous response will be calculated using the length and width of the wheal and flare response to a standardized amount of allergen extract.
  3. Eczema Area and Severity Index (EASI) score.

Exploratory endpoints

1. The number of eosinophils, basophils, eosinophil progenitors, innate lymphoid cell type 2 (ILC2s), cluster of differentiation (CD4+) T cells and hemopoietic cells in skin lesions after 65 days of dosing. The number of cells in skin lesions will be assessed by flow cytometry following digestion of the biopsy and staining with a validated panel of antibodies.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.
Actual Study Start Date : September 4, 2018
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Benralizumab
Fixed dose 30mg benralizumab.
Drug: Benralizumab
Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 & 56.

Placebo Comparator: Placebo Control
Will appear identical in form to benralizumab arm.
Drug: Placebo Control
Subcutaneous placebo injections once per month for 3 months on Days 0, 28 & 56.




Primary Outcome Measures :
  1. Effect of Benralizumab on the number of allergen-induced eosinophils in the skin [ Time Frame: Day 65, 24 hours post-intradermal allergen challenge ]
    The primary objective is to evaluate the effect of benralizumab on the allergen-induced number of eosinophils in the skin assessed by histological examination compared to placebo. Intradermal saline challenge will be used as a control.


Secondary Outcome Measures :
  1. Effect of Benralizumab on the number of allergen induced basophils in the skin [ Time Frame: Day 65, at 24 hours post-intradermal allergen challenge ]
    To evaluate the effect of Benralizumab on the allergen-induced number of basophils in the skin, as assessed by immuno-histochemical staining of a biopsy of the skin wheal compared to placebo.

  2. Effect of Benralizumab on the allergen-induced late phase cutaneous response [ Time Frame: Day 65, at 24 hours post-intradermal allergen challenge ]
    To evaluate the effect of Benralizumab on the allergen-induced late phase cutaneous response by measuring the skin wheal compared to placebo.

  3. Effect of Benralizumab on disease severity [ Time Frame: Day 65, post-treatment ]
    To evaluate the effect of Benralizumab on disease severity by assessing skin lesions using the Eczema Area and Severity Index (EASI) score, compared to placebo. The EASI Score evaluates the area of involvement and severity of AD to provide a total score. Area of involvement includes head & neck, trunk, upper extremities and lower extremities (scores range from 0 (no eruption) to 6 (90-100% of respective body region affected by AD). Severity of AD focuses on erythema, infiltration/papulation, excoriations, and lichenification (scores range from 0 to 3; (none, mild, moderate, severe)). Total EASI scores are computed by summing severity of AD scores from each body location separately, multiplying by area of involvement for that specific body location, and multiplied by a region specific multiplier. The scores for the 4 body regions are then summed to compute a total score. Total scores range from 0 to 72.


Other Outcome Measures:
  1. Effect of benralizumab on the number of eosinophils, basophils, eosinophil progenitor cells and innate lymphoid type 2 cells, CD4+ T cells and hemopoietic cells in skin lesions [ Time Frame: Day 65 post-treatment ]
    To evaluate the effect of benralizumab on the number of eosinophils, basophils, eosinophil progenitor cells and innate lymphoid type 2 cells, CD4+ T cells and hemopoietic cells in skin lesions compared to placebo.

  2. Comparisons of local versus systemic drug-induced changes [ Time Frame: Day 65 post-treatment ]
    To evaluate the effect of benralizumab on the number of eosinophils, basophils, eosinophil progenitor cells and innate lymphoid type 2 cells, CD4+ T cells and hemopoietic cells in blood compared to placebo.

  3. Enumeration of the out-growth potential of the circulating eosinophil/basophil progenitor cell population [ Time Frame: Day 65 post-treatment ]
    Methylcellulose cell cultures from samples of peripheral blood to enumerate the out-growth potential of the circulating eosinophil/basophil progenitor cell population



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients 18 through 65 years of age.
  2. Women of childbearing potential (WOCBP) must not be actively seeking pregnancy, and must use an effective form of birth control (confirmed by the Investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD)/ levonorgestrel Intrauterine system (IUS), Depo-Provera™ injections, oral contraceptive, and Evra Patch™ or Nuvaring™. WOCBP must agree to use effective method of birth control, as defined above, from enrolment, throughout the study duration and within 16 weeks after last dose of IP. They must demonstrate a negative serum pregnancy test at screening and demonstrate a negative urine pregnancy test immediately before each dose of study drug or placebo. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following age-specific requirements apply:

    • Women <50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
    • Women ≥50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
  3. All male patients who are sexually active must agree to use an acceptable method of contraception (condom with or without spermicide, vasectomy) from the first dose of investigational product (IP) until 16 weeks after their last dose.
  4. General good health
  5. Moderate to severe atopic dermatitis
  6. Able to understand and give written informed consent and has signed a written informed consent form approved by the investigator's Research Ethics Board (REB)

The following inclusion criteria must be met for entry into the dosing phase of the study:

  1. Positive skin-prick test to common aeroallergens (including cat, dust mite, grass, pollen)
  2. Positive late cutaneous response to intradermal allergen challenge

Exclusion Criteria:

  1. History of anaphylaxis to any biologic therapy or vaccine
  2. History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or light headedness, as judged by the investigator
  3. Any history or symptoms of cardiovascular disease, particularly coronary artery disease, arrhythmias, hypertension, or congestive heart failure
  4. Any history or symptoms of significant neurologic disease, including transient ischemic attack (TIA), stroke, seizure disorder, or behavioral disturbances
  5. Any history or symptoms of clinically significant autoimmune disease
  6. Any history of clinically significant haematologic abnormality, including coagulopathy or any history of chronic treatment with anticoagulants (e.g. warfarin, etc) or antiplatelet agent (e.g, aspirin, etc)
  7. Clinically significant abnormalities in laboratory test results at enrolment and during the screening period (including complete blood count, coagulation, chemistry panel and urinalysis) unless judged not significant by the investigator.
  8. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.5 times the upper limit of normal (ULN) confirmed during screening period
  9. Being pregnant or lactating or have positive serum pregnancy test at enrolment or positive urine pregnancy test during the study
  10. Concomitant disease or condition which could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease
  11. Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study
  12. Presence of skin comorbidities that may interfere with study assessments
  13. History of cancer: Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to the date informed consent. Patients who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date of informed consent.
  14. Patient who has a scheduled in-patient surgery or hospitalization during the study.
  15. History of Guillain-Barré syndrome
  16. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy
  17. Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol
  18. A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test
  19. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
  20. Receipt of any marketed (eg omalizumab) or investigational biologic within 4 months or 5 half-lives prior to randomization is obtained, whichever is longer
  21. Treatment with an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before the baseline visit
  22. Any allergen immunotherapy within 4 months prior to or throughout the study.
  23. Having used any of the following treatments within 4 weeks before the Day -2 baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during study:

    1. Immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon gamma (IFN-γ), Janus kinase inhibitors, azathioprine, methotrexate, etc.)
    2. Phototherapy for AD
  24. Any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer
  25. Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (patients may continue using stable doses of such moisturizers if initiated before the screening visit)
  26. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit
  27. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. Note: patients may be re-screened after infection resolves
  28. Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment
  29. Planned or anticipated major surgical procedure during the patient's participation in this study
  30. Receipt of live attenuated vaccines 30 days prior to the date of randomization. Receipt of inactive/killed vaccinations (eg, inactive influenza) are allowed provided they are not administered within 1 week before/after any IP administration.
  31. Patient is a member of the investigational team or his/her immediate family
  32. Pregnant woman
  33. Previously received benralizumab (MEDI-563)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03563066


Contacts
Layout table for location contacts
Contact: Gail Gauvreau, PhD 905-525-9140 ext 22791 gauvreau@mcmaster.ca
Contact: Hermenio Lima, MD/PhD 905-525-9140 ext 24881 hlima@mcmaster.ca

Locations
Layout table for location information
Canada, Ontario
McMaster Cardio-Respiratory Research Lab Recruiting
Hamilton, Ontario, Canada, L8N 3Z5
Contact: Gail Gauvreau, PhD       gauvreau@mcmaster.ca   
Principal Investigator: Gail Gauvreau, PhD         
Sponsors and Collaborators
McMaster University
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Gail Gauvreau, PhD McMaster University

Layout table for additonal information
Responsible Party: McMaster University
ClinicalTrials.gov Identifier: NCT03563066     History of Changes
Other Study ID Numbers: ESR-16-12430
First Posted: June 20, 2018    Key Record Dates
Last Update Posted: March 8, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by McMaster University:
Skin Lesions
Benralizumab
Eosinophils
Intra-dermal challenge
Anti-inflammatory agents
Physiological Effects of Drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Benralizumab
Dermatitis, Atopic
Genetic Diseases, Inborn
Skin Diseases, Genetic
Dermatitis
Skin Diseases
Skin Diseases, Eczematous
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Asthmatic Agents
Respiratory System Agents